Back to top
more

Biogen (BIIB)

(Real Time Quote from BATS)

$228.94 USD

228.94
487,925

-6.38 (-2.71%)

Updated May 16, 2024 02:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BIIB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Biogen Inc. [BIIB]

Reports for Purchase

Showing records 641 - 660 ( 799 total )

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 641

01/17/2017

Company Report

Pages: 9

Price: 24.95

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 642

01/16/2017

Company Report

Pages: 9

Price: 24.95

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 643

01/13/2017

Company Report

Pages: 9

Price: 24.95

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 644

12/20/2016

Company Report

Pages: 9

Price: 24.95

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 645

12/13/2016

Company Report

Pages: 9

Price: 24.95

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 646

12/12/2016

Daily Note

Pages: 5

Our Thoughts on Aducanumab and Solanezumab Data From CTAD

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 647

11/25/2016

Daily Note

Pages: 4

What Does the Solanezumab Miss Mean for Aducanumab

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 648

11/21/2016

Industry Report

Pages: 10

2016 World Orphan Drug Congress Recap: Emerging Trends in Rare Disease Therapeutics

Provider: Rodman & Renshaw, Co.

Price: 25.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 649

11/16/2016

Company Report

Pages: 8

Price: 24.95

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 650

10/27/2016

Company Report

Pages: 6

A Means to Minimize ARIA-E? We Look to Interim Analysis of Cohorts 8 and 9 of PRIME at CTAD

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 651

10/20/2016

Company Report

Pages: 8

Price: 24.95

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 652

10/10/2016

Daily Note

Pages: 3

An Update From the World Muscle Society Congress: ENDEAR and NURTURE

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 653

09/21/2016

Industry Report

Pages: 5

A Closer Look at Solanezumab Ahead of EXPEDITION 3 Readout

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 654

09/19/2016

Daily Note

Pages: 4

Our Takeaways From SYNERGY

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 655

09/19/2016

Company Report

Pages: 8

Price: 24.95

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 656

09/06/2016

Daily Note

Pages: 4

We Continue to View PRIME as a Positive Demonstration of Aducanumab’s PK/PD

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 657

08/16/2016

Company Report

Pages: 8

Price: 24.95

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 658

08/12/2016

Company Report

Pages: 8

Price: 24.95

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 659

08/10/2016

Company Report

Pages: 8

Price: 24.95

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 660

08/02/2016

Daily Note

Pages: 3

Our View on ENDEAR and the Nusinersen Opportunity

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party